WallStSmart

Merck & Company Inc (MRK)vsUniverse Pharmaceuticals Inc (UPC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 368169% more annual revenue ($65.77B vs $17.86M). MRK leads profitability with a 13.6% profit margin vs -20.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

UPC

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 9.0
Piotroski: 5/9Altman Z: 3.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-42.4%)

Margin of Safety

-42.4%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for UPC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

UPC3 strengths · Avg: 9.7/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.0710/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.169/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

UPC4 concerns · Avg: 2.3/10
Market CapQuality
$2.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-39.6%2/10

ROE of -39.6% — below average capital efficiency

Revenue GrowthGrowth
-14.1%2/10

Revenue declined 14.1%

EPS GrowthGrowth
-82.0%2/10

Earnings declined 82.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : UPC

The strongest argument for UPC centers on Price/Book, Altman Z-Score, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : UPC

The primary concerns for UPC are Market Cap, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while UPC is a turnaround play — different risk/reward profiles.

UPC carries more volatility with a beta of 1.60 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Universe Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Universe Pharmaceuticals INC, a pharmaceutical company, is engaged in the manufacture, marketing, distribution and sale of products derived from traditional Chinese medicine in China.

Visit Website →

Want to dig deeper into these stocks?